WO2000027381A3 - Topical application of muscarinic agents such as neostigmine for treatment of acne and other inflammatory conditions - Google Patents

Topical application of muscarinic agents such as neostigmine for treatment of acne and other inflammatory conditions Download PDF

Info

Publication number
WO2000027381A3
WO2000027381A3 PCT/US1999/026235 US9926235W WO0027381A3 WO 2000027381 A3 WO2000027381 A3 WO 2000027381A3 US 9926235 W US9926235 W US 9926235W WO 0027381 A3 WO0027381 A3 WO 0027381A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
acne
inflammatory conditions
neostigmine
muscarinic agents
Prior art date
Application number
PCT/US1999/026235
Other languages
French (fr)
Other versions
WO2000027381A2 (en
Inventor
Khoury George F El
Original Assignee
Khoury George F El
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Khoury George F El filed Critical Khoury George F El
Priority to AU16097/00A priority Critical patent/AU1609700A/en
Publication of WO2000027381A2 publication Critical patent/WO2000027381A2/en
Publication of WO2000027381A3 publication Critical patent/WO2000027381A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)

Abstract

Treatment of acne through topical administration is an aspect of the present invention. Specifically, muscarinic agents may be applied in any therapeutically acceptable carrier including gels, creams, lotions, and sprays. Therapeutic effects observed with the present invention include decrease in redness, swelling, and inflammation. Treatment of other inflammatory conditions is also disclosed. Treatment of suitable conditions in accordance with the present invention results in significant improvements in healing of those conditions.
PCT/US1999/026235 1998-11-09 1999-11-08 Topical application of muscarinic agents such as neostigmine for treatment of acne and other inflammatory conditions WO2000027381A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU16097/00A AU1609700A (en) 1998-11-09 1999-11-08 Topical application of muscarinic agents such as neostigmine for treatment of acne and other inflammatory conditions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/188,328 1998-11-09
US09/188,328 US5994330A (en) 1998-11-09 1998-11-09 Topical application of muscarinic agents such as neostigmine for treatment of acne and other inflammatory conditions

Publications (2)

Publication Number Publication Date
WO2000027381A2 WO2000027381A2 (en) 2000-05-18
WO2000027381A3 true WO2000027381A3 (en) 2000-11-23

Family

ID=22692710

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/026235 WO2000027381A2 (en) 1998-11-09 1999-11-08 Topical application of muscarinic agents such as neostigmine for treatment of acne and other inflammatory conditions

Country Status (4)

Country Link
US (1) US5994330A (en)
AU (1) AU1609700A (en)
TW (1) TWI227134B (en)
WO (1) WO2000027381A2 (en)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6133326A (en) * 1994-08-31 2000-10-17 Pfizer Inc Compositions and methods for decreasing sebum production
US7396526B1 (en) 1998-11-12 2008-07-08 Johnson & Johnson Consumer Companies, Inc. Skin care composition
US8188043B2 (en) * 1999-07-28 2012-05-29 The Board Of Trustees Of The Leland Stanford Jr. University Nicotine in therapeutic angiogenesis and vasculogenesis
AU1490401A (en) * 1999-11-16 2001-05-30 George F. El Khoury Topical application of muscarinic analgesic drugs such as neostigmine
US6610713B2 (en) * 2000-05-23 2003-08-26 North Shore - Long Island Jewish Research Institute Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
US8914114B2 (en) 2000-05-23 2014-12-16 The Feinstein Institute For Medical Research Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
KR20020027198A (en) * 2000-10-02 2002-04-13 차알스 제이. 메츠 Method for reduction of inflammation and erythema
US20040213754A1 (en) * 2000-10-02 2004-10-28 Cole Curtis A. Method for cleansing sensitive skin using an alkanolamine
US20050238730A1 (en) * 2001-11-21 2005-10-27 Agnes Le Fur Compositions comprising an ethanolamine derivative and organic metal salts
EP1487494A2 (en) * 2002-02-26 2004-12-22 North Shore-Long Island Jewish Research Institute Inhibition of inflammatory cytokine production by stimulation of brain muscarinic receptors
US6723755B2 (en) 2002-06-12 2004-04-20 Piotr Chomczynski Method of treating rosacea
JP4387639B2 (en) * 2002-07-16 2009-12-16 久光製薬株式会社 Transdermal absorption preparation
US10912712B2 (en) 2004-03-25 2021-02-09 The Feinstein Institutes For Medical Research Treatment of bleeding by non-invasive stimulation
US8729129B2 (en) 2004-03-25 2014-05-20 The Feinstein Institute For Medical Research Neural tourniquet
US7812057B2 (en) * 2004-08-25 2010-10-12 Molecular Research Center, Inc. Cosmetic compositions
GB2419093A (en) * 2004-10-12 2006-04-19 Ernir Snorrason Acetylcholinesterase inhibitors for the treatment of skin
EP2008660A1 (en) * 2004-10-12 2008-12-31 Ernir Snorrason Inhibitors of acetylcholinesterase for treating skin diseases
US11207518B2 (en) 2004-12-27 2021-12-28 The Feinstein Institutes For Medical Research Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
EP2298410B1 (en) 2004-12-27 2013-10-09 The Feinstein Institute for Medical Research Treating inflammatory disorders by electrical vagus nerve stimulation
ITRM20050248A1 (en) * 2005-05-20 2006-11-21 Sigma Tau Ind Farmaceuti USE OF ACID ADAMANTYL METOXIDIDENYL PROPENOIC FOR THE TREATMENT OF SKIN PATHOLOGIES.
US7939567B2 (en) * 2006-02-24 2011-05-10 Blue Blood Biotech Corp. Dextromethorphan-based method for treating acne
WO2009029614A1 (en) 2007-08-27 2009-03-05 The Feinstein Institute For Medical Research Devices and methods for inhibiting granulocyte activation by neural stimulation
US20130165508A1 (en) * 2007-09-13 2013-06-27 Robert C. Stover Methods and formulations for treating ineffective or decreased esophagal motility
US9211409B2 (en) 2008-03-31 2015-12-15 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation of T-cell activity
US9662490B2 (en) 2008-03-31 2017-05-30 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
CN102215909B (en) 2008-11-18 2014-09-10 赛博恩特医疗器械公司 Devices and methods for optimizing electrode placement for anti-inflamatory stimulation
US9211410B2 (en) 2009-05-01 2015-12-15 Setpoint Medical Corporation Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US8996116B2 (en) 2009-10-30 2015-03-31 Setpoint Medical Corporation Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
AU2010258792B2 (en) 2009-06-09 2015-07-02 Setpoint Medical Corporation Nerve cuff with pocket for leadless stimulator
US11051744B2 (en) 2009-11-17 2021-07-06 Setpoint Medical Corporation Closed-loop vagus nerve stimulation
US9833621B2 (en) 2011-09-23 2017-12-05 Setpoint Medical Corporation Modulation of sirtuins by vagus nerve stimulation
CN105126248B (en) 2009-12-23 2018-06-12 赛博恩特医疗器械公司 For treating the nerve stimulation apparatus of chronic inflammation and system
WO2012154865A2 (en) 2011-05-09 2012-11-15 Setpoint Medical Corporation Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US9572983B2 (en) 2012-03-26 2017-02-21 Setpoint Medical Corporation Devices and methods for modulation of bone erosion
US9023399B2 (en) 2012-11-16 2015-05-05 NU Technology, LLC Water-soluble anti-inflammatory cream with natural ingredients base
US8613961B1 (en) 2013-01-09 2013-12-24 NU Technology, LLC Dermatological cream with natural ingredients base
US11311725B2 (en) 2014-10-24 2022-04-26 Setpoint Medical Corporation Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
US11406833B2 (en) 2015-02-03 2022-08-09 Setpoint Medical Corporation Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
US10596367B2 (en) 2016-01-13 2020-03-24 Setpoint Medical Corporation Systems and methods for establishing a nerve block
US10314501B2 (en) 2016-01-20 2019-06-11 Setpoint Medical Corporation Implantable microstimulators and inductive charging systems
US11471681B2 (en) 2016-01-20 2022-10-18 Setpoint Medical Corporation Batteryless implantable microstimulators
US10695569B2 (en) 2016-01-20 2020-06-30 Setpoint Medical Corporation Control of vagal stimulation
US10583304B2 (en) 2016-01-25 2020-03-10 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
US20180092983A1 (en) * 2016-10-05 2018-04-05 Tian Xin Wang Methods and reagents to treat autoimmune diseases and allergy
WO2019036470A1 (en) 2017-08-14 2019-02-21 Setpoint Medical Corporation Vagus nerve stimulation pre-screening test
US11260229B2 (en) 2018-09-25 2022-03-01 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
IL298193B2 (en) 2020-05-21 2024-01-01 Feinstein Institutes For Medical Research Systems and methods for vagus nerve stimulation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998025614A1 (en) * 1994-08-17 1998-06-18 El Khoury George F Topical application of opioid analgesic drugs such as morphine
WO1999059577A1 (en) * 1998-05-21 1999-11-25 El Khoury George F Topical application of muscarinic analgesic drugs such as neostigmine

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3275510A (en) * 1966-09-27 Topical antitussive preparations
US4416886A (en) * 1981-07-29 1983-11-22 Dermall Limited Method of treating pruritis and composition therefor
US4626539A (en) * 1984-08-10 1986-12-02 E. I. Dupont De Nemours And Company Trandermal delivery of opioids
US4897260A (en) * 1987-05-22 1990-01-30 The Rockefeller University Compositions that affect suppression of cutaneous delayed hypersensitivity and products including same
EP0295836B1 (en) * 1987-06-16 1992-09-02 Btg International Limited Use of dioxopiperidine derivatives for the manufacture of topical medicaments as analgesics
US5069909A (en) * 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine
AU1183092A (en) * 1991-02-06 1992-09-07 Guy Parent Antalgic ointment
US5520920A (en) * 1992-08-28 1996-05-28 Alcon Laboratories, Inc. Use of certain anionic surfactants to enhance antimicrobial effectiveness of ophthalmic compositions
US5834480A (en) * 1997-06-13 1998-11-10 Elkhoury; George F. Topical application of opioids for treatment of acne and sebaceous gland disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998025614A1 (en) * 1994-08-17 1998-06-18 El Khoury George F Topical application of opioid analgesic drugs such as morphine
WO1999059577A1 (en) * 1998-05-21 1999-11-25 El Khoury George F Topical application of muscarinic analgesic drugs such as neostigmine

Also Published As

Publication number Publication date
AU1609700A (en) 2000-05-29
WO2000027381A2 (en) 2000-05-18
US5994330A (en) 1999-11-30
TWI227134B (en) 2005-02-01

Similar Documents

Publication Publication Date Title
WO2000027381A3 (en) Topical application of muscarinic agents such as neostigmine for treatment of acne and other inflammatory conditions
CA2328368A1 (en) Anti-inflammatory agents
WO2000044367A3 (en) A pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same
CY1111463T1 (en) CLONIDINE PREPARATIONS
WO2003028667A3 (en) Semisolid topical hormonal compositions and methods for treatment
EP1419803A3 (en) Pharmaceutical composition for topical administration comprising an antiviral substance and a glucocorticoid
WO1996012498A3 (en) Dermatological compositions containing benzoyl peroxide and a compound reducing skin irritation
EP1510213A3 (en) Penetration enhancing and irritation reducing systems comprising testosterone
EP1439832A4 (en) Method of treating acne vulgaris using avermectin compound
MXPA04000654A (en) Dermal therapy using phosphate derivatives of electron transfer agents.
WO2003018619A3 (en) Antimicrobial and anti-inflammatory peptides
CA2015838A1 (en) Method of topically treating acne vulgaris
AU674142B2 (en) Use of cosmetic composition
AU3459689A (en) Treatment of skin disorders
WO2001041550A3 (en) Topical anesthetic formulation
CA2157836A1 (en) L-carnitine salt and cosmetic and pharmaceutical compositions containing same for treating dermatoses
CA2275167A1 (en) The topical use of kappa opioid agonists to treat ocular pain
WO2000072835A3 (en) Topical application of muscarinic and opioid agents for treatment of tinnitus
NZ336600A (en) Use of dichlorobenzyl alcohol for preparing a preparation for topical treatment of inflammation
CA2294482A1 (en) Treatment of aging skin
AU4538893A (en) Treatment for cutaneous pain, itching and inflammation with topical stannous fluoride
WO2003032915A3 (en) Viral inhibition by n-docosanol
IL136807A0 (en) Topical carbamazepine formulation and methods of use
AU2877800A (en) Short contact treatment of psoriasis with topical retinoids
AU5523298A (en) Novel topical formulation of anti-inflammatory drugs for the treatment of localized pain

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: AU

Ref document number: 2000 16097

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase